Voyager Therapeutics (NASDAQ:VYGR) had its price objective dropped by research analysts at Robert W. Baird from $31.00 to $27.00 in a research report issued on Thursday. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s price objective would indicate a potential upside of 119.16% from the company’s previous close.
Several other research analysts also recently issued reports on VYGR. Wedbush reaffirmed an “outperform” rating and set a $28.00 price target (up previously from $18.00) on shares of Voyager Therapeutics in a research note on Thursday. ValuEngine raised Voyager Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday. BidaskClub downgraded Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, September 20th. Morgan Stanley set a $13.00 price target on Voyager Therapeutics and gave the stock a “hold” rating in a research note on Thursday. Finally, HC Wainwright set a $30.00 target price on shares of Voyager Therapeutics and gave the company a “buy” rating in a research note on Wednesday, August 8th. Four research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Voyager Therapeutics has a consensus rating of “Buy” and a consensus target price of $28.00.
NASDAQ:VYGR opened at $12.32 on Thursday. Voyager Therapeutics has a 52-week low of $11.00 and a 52-week high of $31.91.
Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Wednesday, November 7th. The company reported ($0.63) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.15. The business had revenue of $2.09 million during the quarter, compared to the consensus estimate of $3.02 million. Voyager Therapeutics had a negative return on equity of 73.99% and a negative net margin of 648.40%. Equities research analysts predict that Voyager Therapeutics will post -2.87 earnings per share for the current fiscal year.
In other news, Director James A. Geraghty bought 3,000 shares of the business’s stock in a transaction that occurred on Friday, August 17th. The stock was purchased at an average price of $18.31 per share, with a total value of $54,930.00. Following the purchase, the director now owns 73,588 shares of the company’s stock, valued at approximately $1,347,396.28. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Glenn Pierce bought 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, September 12th. The stock was purchased at an average cost of $18.44 per share, with a total value of $92,200.00. The disclosure for this purchase can be found here. Insiders purchased a total of 11,000 shares of company stock valued at $205,300 in the last three months. 33.60% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the stock. Oppenheimer & Co. Inc. raised its stake in Voyager Therapeutics by 37.5% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 22,000 shares of the company’s stock valued at $430,000 after purchasing an additional 6,000 shares during the last quarter. Trustees of Princeton University acquired a new position in Voyager Therapeutics in the 2nd quarter valued at about $3,979,000. Cim Investment Mangement Inc. acquired a new position in Voyager Therapeutics in the 2nd quarter valued at about $400,000. BlackRock Inc. increased its stake in shares of Voyager Therapeutics by 18.8% during the 1st quarter. BlackRock Inc. now owns 1,438,029 shares of the company’s stock valued at $27,020,000 after acquiring an additional 227,266 shares during the last quarter. Finally, Schwab Charles Investment Management Inc. increased its stake in shares of Voyager Therapeutics by 17.1% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 101,576 shares of the company’s stock valued at $1,985,000 after acquiring an additional 14,849 shares during the last quarter. 85.09% of the stock is owned by hedge funds and other institutional investors.
About Voyager Therapeutics
Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trials for the treatment of advanced Parkinson's disease.
Featured Article: Day Trading
Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.